Bezisterim

New Phase 2 trial data has been released on Bezisterim as a potential treatment for long COVID, according to Psychiatric Times. The drug, an anti-inflammatory compound, is being studied for patients suffering from persistent symptoms after coronavirus infection. The findings are drawing attention as treatment options for long COVID remain limited and demand for effective therapies continues to grow.